肺段切除术与肺叶切除术在意外淋巴结转移的非小细胞肺癌中生存获益相当
本研究基于美国国家癌症数据库,评估临床T1N0但术后病理发现N1/N2淋巴结转移的非小细胞肺癌患者接受肺叶切除术或肺段切除术后的生存差异。通过倾向性评分匹配分析,两组5年生存率无显著差异,而辅助化疗与更好的生存相关。
要点
- 临床T1N0患者中意外N1/N2转移率低,肺段切除与肺叶切除5年生存无差异。
- 辅助化疗可显著改善意外N1/N2转移患者的生存,与手术方式无关。
核心结论
- 对于临床T1N0且意外发现病理N1/N2淋巴结转移的非小细胞肺癌,肺叶切除术与肺段切除术的生存相似。
- 辅助化疗可显著改善淋巴结转移(N1/N2)患者的生存,且与解剖性肺切除类型无关。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库(National Cancer Database)。
- 纳入临床T1N0、病理N1/N2的非小细胞肺癌患者,接受肺叶切除术或肺段切除术。
- 使用倾向性评分模型评估两组生存差异,Cox回归分析评估总体生存预测因素。
主要发现
- 2004至2015年间,临床T1N0M0患者中,肺段切除组意外病理N1发生率为2.5%(228/9118),肺叶切除组为6.7%(8915/132604)。
- 意外病理N2发生率在肺段切除组为2.4%(224/9118),肺叶切除组为3.9%(5192/132604)。
临床怎么用
- 对于临床T1N0患者,若行意向性肺段切除时发现淋巴结阳性,转为肺叶切除可能并未带来生存获益。
- 意外N1/N2淋巴结转移患者应接受辅助化疗以改善生存。
局限性
- 回顾性研究设计,可能存在选择偏倚和未测量混杂因素。
- 数据库研究可能缺乏部分临床细节,如具体手术方式、切缘状态等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Conversion to lobectomy is typically performed when positive lymph nodes are found during intentional segmentectomy. Our objective was to evaluate survival after lobectomy and segmentectomy in patients with unsuspected nodal metastases. METHODS: The National Cancer Database was queried for patients with clinical T1N0, pathological N1/N2 non-small cell lung cancer (NSCLC) who underwent either lobectomy or segmentectomy. Survival differences between the 2 groups were evaluated using a propensity score model. Cox regression analysis was used to evaluate predictors of overall survival, including adjuvant treatment. Statistical analysis was done using SPSS version 21.0 (IBM Corp, Armonk, NY). RESULTS: Between 2004 and 2015, unsuspected pathological N1 disease for clinical T1N0M0 NSCLC was found in 2.5% (228/9118) and 6.7% (8915/132,604) of patients who underwent segmentectomy and lobectomy, respectively. The incidence of unsuspected pathological N2 disease for clinical T1N0M0 NSCLC was 2.4% (224/9118) after segmentectomy and 3.9% (5192/132,604) after lobectomy. Using propensity matched pairs (227 pairs for N1 and 215 for N2), segmentectomy showed equivalent 5-year survival compared with lobectomy for the N1 group (41.9% vs 44.3%; P = .35), and N2 group (41.6% vs 37.2%; P = .99). In a multivariable model, adjuvant chemotherapy was associated with better survival of patients with unsuspected N1 (hazard ratio, 0.613; 95% confidence interval, 0.536-0.700; P < .001) and N2 (hazard ratio, 0.684; 95% confidence interval, 0.583-0.802; P < .001) nodal metastases. CONCLUSIONS: Survival is similar between lobectomy and segmentectomy for clinical T1N0 and unsuspected pathological N1/N2 nodal metastases. The use of adjuvant chemotherapy significantly improves survival in patients with lymph node metastasis (N1/N2) independent of the type of anatomic lung resection.
引用
- Razi SS, Nguyen D, Villamizar N, et al. Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease. J Thorac Cardiovasc Surg. 2019. PMID: 31928821. doi:10.1016/j.jtcvs.2019.10.165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。